October 5, 2022
Perfectus Biomed Group are delighted to announce that they are now a part of NAMSA
As the global leader of the medical device testing industry since 1967, NAMSA has amassed a large breadth and depth of therapeutic expertise.
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group, a UK founded laboratory, providing customized microbiological services.
Best-in-class global MedTech solutions
Sam Westgate, Perfectus Biomed Group CEO, said:
Perfectus Biomed Group is delighted to join NAMSA in its mission to deliver best-in-class global MedTech solutions through its people, expertise and technology. With similar values and expertise to customize solutions for clients across the globe, we are well aligned to achieve future success for both our clients and combined organizations. With the complimentary expertise and resources of NAMSA, we will serve our clients in an even greater capacity and we look forward to joining the world’s leading CRO for full continuum development services. Westgate concluded.
As the global leader of the medical device testing industry since 1967, NAMSA has amassed a large breadth and depth of therapeutic expertise and knowledge across the continuum of microbiology and in vitro testing services. NAMSA’s world-class testing capabilities include all areas of microbiological sterility, validation and quality assurance solutions in its well-equipped facilities in the U.S. and France.
Unmatched level of expertise
Dr. Christophe Berthoux, NAMSA CEO, said:
NAMSA very much looks forward to expanding its European suite of laboratory services with the addition of Perfectus Biomed Group. Perfectus brings an unmatched level of expertise and depth of knowledge in customized microbiological testing solutions. This know-how and extreme proficiency in microbiological research will help us to further support Clients and continue to provide cutting-edge solutions for medical device testing and research.
If you currently have a testing project with Perfectus, then rest assured it will not be affected by this announcement. A member of their commercial team will be in touch very soon to answer any questions you may have.
You can be confident that you will continue to receive the same high-quality service you have grown to expect from Perfectus Biomed Group. This transition enables their team access to broader services, expertise and resources.
Their contact details, including email and telephone numbers, won’t be changing. Key contacts within the company will remain the same. If you have any burning questions their commercial team can be contacted at email@example.com or the UK contact number is 01925 737237 and the US contact number is 307 264 1572.